Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT4406F in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06044350Phase 2Active, not recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAT4406F in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Pharmacodynamics up to 3 years, Pharmacokinetics up to 49 months and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
BAT4406F
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06044350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044350.